Literature DB >> 16600988

Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease.

Austen J Milnerwood1, Damian M Cummings, Glenn M Dallérac, Jacki Y Brown, Sarat C Vatsavayai, Mark C Hirst, Payam Rezaie, Kerry P S J Murphy.   

Abstract

Huntington's disease (HD) is a fatal neurodegenerative disorder characterized by progressive motor, psychiatric and cognitive decline. Marked neuronal loss occurs in the cortex and striatum. HD is inherited in an autosomal dominant fashion and caused by a trinucleotide repeat expansion (CAG) in the gene encoding the protein huntingtin. Predictive genetic testing has revealed early cognitive deficits in asymptomatic gene carriers at a time when there is little evidence for cell death, suggesting that impaired cognition results from a cellular or synaptic deficit, such as aberrant synaptic plasticity. Altered hippocampal long-term potentiation has been reported in mouse models of HD; however, the relationship between synaptic dysfunction and phenotype progression has not previously been characterized. We examined the age-dependency of aberrant hippocampal synaptic plasticity in the R6/1 mouse model of HD. Long-term depression (LTD) is a developmentally regulated form of plasticity, which normally declines by early adulthood. Young R6/1 mice follow the same pattern of LTD expression as controls, in that they express LTD in the first weeks of life, and then lose the ability with age. Unlike controls, R6/1 synapses later regain the ability to support LTD. This is associated with nuclear localization of mutant huntingtin, but occurs months prior to the formation of nuclear aggregates. We present the first detailed description of a progressive derailment of a functional neural correlate of cognitive processing in HD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16600988     DOI: 10.1093/hmg/ddl092

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  47 in total

1.  Changes in Dopamine Signalling Do Not Underlie Aberrant Hippocampal Plasticity in a Mouse Model of Huntington's Disease.

Authors:  Glenn M Dallérac; Damian M Cummings; Mark C Hirst; Austen J Milnerwood; Kerry P S J Murphy
Journal:  Neuromolecular Med       Date:  2016-01-18       Impact factor: 3.843

2.  Oxidative metabolism in YAC128 mouse model of Huntington's disease.

Authors:  James Hamilton; Jessica J Pellman; Tatiana Brustovetsky; Robert A Harris; Nickolay Brustovetsky
Journal:  Hum Mol Genet       Date:  2015-06-03       Impact factor: 6.150

3.  Integrative Analysis of Disease Signatures Shows Inflammation Disrupts Juvenile Experience-Dependent Cortical Plasticity.

Authors:  Milo R Smith; Poromendro Burman; Masato Sadahiro; Brian A Kidd; Joel T Dudley; Hirofumi Morishita
Journal:  eNeuro       Date:  2017-01-18

4.  Tonic mGluR5/CB1-dependent suppression of inhibition as a pathophysiological hallmark in the striatum of mice carrying a mutant form of huntingtin.

Authors:  Anton Dvorzhak; Marcus Semtner; Donald S Faber; Rosemarie Grantyn
Journal:  J Physiol       Date:  2012-12-10       Impact factor: 5.182

5.  The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6/2 Huntington's disease mice.

Authors:  A Reiner; D C Lafferty; H B Wang; N Del Mar; Y P Deng
Journal:  Neurobiol Dis       Date:  2012-03-27       Impact factor: 5.996

6.  Neurotrophin receptor p75(NTR) mediates Huntington's disease-associated synaptic and memory dysfunction.

Authors:  Verónica Brito; Albert Giralt; Lilian Enriquez-Barreto; Mar Puigdellívol; Nuria Suelves; Alfonsa Zamora-Moratalla; Jesús J Ballesteros; Eduardo D Martín; Nuria Dominguez-Iturza; Miguel Morales; Jordi Alberch; Sílvia Ginés
Journal:  J Clin Invest       Date:  2014-09-02       Impact factor: 14.808

Review 7.  Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms.

Authors:  Carlos Cepeda; Damian M Cummings; Véronique M André; Sandra M Holley; Michael S Levine
Journal:  ASN Neuro       Date:  2010-04-07       Impact factor: 4.146

Review 8.  The role of dopamine in Huntington's disease.

Authors:  Carlos Cepeda; Kerry P S Murphy; Martin Parent; Michael S Levine
Journal:  Prog Brain Res       Date:  2014       Impact factor: 2.453

9.  Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease.

Authors:  Damian M Cummings; Véronique M André; Besim O Uzgil; Steven M Gee; Yvette E Fisher; Carlos Cepeda; Michael S Levine
Journal:  J Neurosci       Date:  2009-08-19       Impact factor: 6.167

10.  Prostaglandin E2 EP1 receptor antagonist improves motor deficits and rescues memory decline in R6/1 mouse model of Huntington's disease.

Authors:  Marta Anglada-Huguet; Xavier Xifró; Albert Giralt; Alfonsa Zamora-Moratalla; Eduardo D Martín; Jordi Alberch
Journal:  Mol Neurobiol       Date:  2013-11-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.